Go Pro
NYSE:CPHI

China Pharma (CPHI) Stock Price, News & Analysis

China Pharma logo
$1.11 -0.19 (-14.62%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$1.12 +0.01 (+0.81%)
As of 07/31/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About China Pharma Stock (NYSE:CPHI)

Advanced

Key Stats

Today's Range
$1.08
$1.28
50-Day Range
$0.57
$8.10
52-Week Range
$0.38
$19.19
Volume
602,221 shs
Average Volume
1.94 million shs
Market Capitalization
$44.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Receive CPHI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for China Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CPHI Stock News Headlines

Critical Comparison: MindWalk (NASDAQ:HYFT) & China Pharma (NYSE:CPHI)
This could help save your retirement
Murray Stahl is a Wall Street money manager who put more than half of his $9 billion firm into a single stock - one that returned 46,950% between 2002 and 2026, according to Morningstar. Whitney Tilson of Stansberry Research believes this company, which sits at the center of AI and another major U.S. industry, could be a rare retirement-building opportunity. He's revealing the name and ticker for free.tc pixel
See More Headlines

CPHI Stock Analysis - Frequently Asked Questions

China Pharma's stock was trading at $1.21 at the start of the year. Since then, CPHI stock has decreased by 8.3% and is now trading at $1.11.

China Pharma Holdings, Inc. (NYSE:CPHI) posted its quarterly earnings data on Wednesday, August, 15th. The company reported ($100.00) EPS for the quarter. The business earned $3.17 million during the quarter. China Pharma had a negative net margin of 85.56% and a negative trailing twelve-month return on equity of 63.93%.

China Pharma's stock reverse split on the morning of Tuesday, April 15th 2025.The 1-10 reverse split was announced on Friday, April 4th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 14th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of CPHI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that China Pharma investors own include Micron Technology (MU), Inovio Pharmaceuticals (INO), Tonix Pharmaceuticals (TNXP) and Bionano Genomics (BNGO).

Company Calendar

Last Earnings
8/15/2018
Today
8/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:CPHI
CIK
1106644
Employees
250
Year Founded
1999

Profitability

EPS (Trailing Twelve Months)
($0.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.08 million
Net Margins
-85.56%
Pretax Margin
-85.56%
Return on Equity
-63.93%
Return on Assets
-31.42%

Debt

Debt-to-Equity Ratio
0.22
Current Ratio
0.79
Quick Ratio
0.26

Sales & Book Value

Annual Sales
$3.99 million
Price / Sales
11.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.70 per share
Price / Book
1.59

Miscellaneous

Outstanding Shares
40,522,000
Free Float
15,918,000
Market Cap
$44.98 million
Optionable
Not Optionable
Beta
1.14

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NYSE:CPHI) was last updated on 8/2/2026 by MarketBeat.com Staff.
From Our Partners